Tuition Hikes and International Student Visa Restrictions Fuel Demand for Investment Migration Programs
2.9.2019 19:44:00 EEST | Business Wire | Press release
As global headlines are dominated by the effects of changing immigration policies in the UK and the US, there is one consequence that has gone largely unnoticed: a significant decline in international student numbers. Latest statistics show that top universities have seen international enrollment figures drop significantly in response to new restrictions on student visas in the US, uncertainty over Brexit and the rights of EU citizens in the UK, and tuition hikes in both countries.
Seeking to avoid these pitfalls, high-net-worth individuals (HNWIs) are pursuing alternative residence or citizenship rights that will allow their children to fulfil their academic aspirations without becoming entangled in risky or unpredictable visa application processes.
Dr. Juerg Steffen, CEO of investment migration firm Henley & Partners, says education is a fundamental priority for most clients. “There are many reasons for acquiring alternative citizenship or residence, but ultimately, it comes down to long-term stability and security – a classic investment hedge against potential volatility. The dramatically expanded education options that open up by having alternative citizenship or residence in a desirable location is often a decisive factor for families when they are considering making this kind of investment.”
The UK Investor Immigration Program is ideal for investors seeking to take advantage of the UK’s excellent primary, secondary, and tertiary education services. As noted by the Knight Frank Global Wealth Report, although Australia, Canada, Switzerland, the US, and a number of other countries all attract students from overseas, the UK’s private boarding schools are still seen as the gold standard by many. At the tertiary level, the Oxford and Cambridge universities are currently ranked number one and two in the world by Times Higher Education, which provides the definitive list of the world’s best universities.
Of the universities in mainland Europe, revered institutions such as Humboldt University of Berlin, Sorbonne University in Paris, and the University of Amsterdam continue to draw wealthy international students, attracted by both the peerless quality of education on offer and the experience of student life in a European capital. For investors wanting to give their children access to these kinds of opportunities, a key advantage of European universities is that fees for EU citizens are much lower than they are for non-EU citizens — up to 50% or more. For an investment of between EUR 1 million and EUR 2.15 million, Malta and Cyprus offer the most popular citizenship-by-investment programs in the EU at present.
Across the Atlantic, the US EB-5 Immigrant Investor Program is an attractive option for those who have their sights set on an American education. The program offers permanent residence in exchange for an investment of USD 500,000 to USD 1 million. The Australia Residence-by-Investment Program is another potential avenue to pursue. Overall, the country is renowned for its education system — one of many reasons it remains the top destination of choice for HNWIs looking to resettle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190902005238/en/
Contact information
Media
Sarah Nicklin
Senior Group PR Manager
sarah.nicklin@henleyglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
